Median progression-free survival was marginally longer with gefitinib than it was with placebo ( 157 months , 95 % CI 123-190 in the gefitinib group vs 117 months , 95 % CI 107-137 in the placebo group ; HR 080 , 95 % CI 066-096 , p = 0020 ) .